a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 2
Not Applicable
- Conditions
- DLB
- Registration Number
- JPRN-UMIN000018813
- Lead Sponsor
- Promedico Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)dozed antidementia drugs except Donepezil within 12 weeks before informed consent 2)bed ridden 3)with severe impairment of visual acuity, auditory sensor and/or communication 4)with neurological degenerative disease except for DLBV criteria, schizophrenia, bipolar disorder and major depression 5)with delirium due to abuse of alcohol, drugs, metabolic toxicity and inflammation 6)inadequate decided by principal investigator 7)with hypersensitivity to components of Donepezil or piperidine derivative 8)dozed investigational drug within 12 weeks before informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method